213 filings
Page 2 of 11
8-K
z7v m2mpk
28 Feb 22
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
4:12pm
8-K
2slvu4ny35dgi5f98
20 Dec 21
Acadia Pharmaceuticals Announces Plan for a Resubmission of its
9:26pm
8-K
41h3ov iol
14 Dec 21
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice
4:52pm
8-K
npqcsdnmmk
6 Dec 21
Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3
5:16pm
8-K
u14wnxva2wh4c
8 Nov 21
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
4:15pm
8-K
1rsndweugbtf
5 Nov 21
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
4:31pm
8-K
aakojhe9yx9 qippor
2 Sep 21
Departure of Directors or Certain Officers
5:00pm
8-K
wn77ua nzhr5s
4 Aug 21
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results
4:15pm
8-K
y3qr0r3j1
24 Jun 21
Submission of Matters to a Vote of Security Holders
5:01pm
8-K
po41jbq
5 May 21
Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results
4:19pm
8-K
7z2q5s
5 Apr 21
Regulation FD Disclosure
8:08am
8-K
f8r2c86ib7
8 Mar 21
Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of
4:30pm
8-K
pncl1 l4w
24 Feb 21
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
4:10pm
8-K
czia ai8l6506kuiji
27 Jan 21
Departure of Directors or Certain Officers
5:26pm
8-K
a8vze6l2hkzu
4 Nov 20
Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results
4:37pm
8-K
ix2rk6 yk8
1 Oct 20
Departure of Directors or Certain Officers
5:30pm
8-K
w0w3m9ju7
25 Aug 20
ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
9:02am
8-K
e5ucxe
6 Aug 20
Departure of Directors or Certain Officers
5:21pm
8-K
js3yx4d8dvooqkz 63c
5 Aug 20
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
4:34pm
8-K
f7djg8y 0dsc
20 Jul 20
ACADIA Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZIDĀ®Ā (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
4:15pm